Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer (SOFIA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00548899
Recruitment Status : Completed
First Posted : October 24, 2007
Last Update Posted : March 9, 2015
Information provided by (Responsible Party):
German Breast Group

Brief Summary:
The purpose of this study is to determine the efficacy and safety of sorafenib in the neoadjuvant setting in patients with primary breast cancer

Condition or disease Intervention/treatment Phase
Breast Cancer Drug: Nexavar (Sorafenib) Phase 2

Detailed Description:
Epirubicin/Cyclophosphamide followed by Paclitaxel (EC/P) is a well tolerated regimen with high clinical activity. Histopathological complete remission after preoperative chemotherapy has a direct correlation with the disease-free and overall survival. The aim of combining a chemotherapy regime with sorafenib in the neoadjuvant setting is to increase the locoregional and systemic outcome of these patients

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 36 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women With Previously Untreated
Study Start Date : November 2007
Actual Primary Completion Date : September 2011
Actual Study Completion Date : December 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Single Arm: All patients receive sorafenib in addition to the established chemotherapy
Drug: Nexavar (Sorafenib)
Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day

Primary Outcome Measures :
  1. to establish the most feasible regimen of EC-P (P-EC) with sorafenib [ Time Frame: Time of surgery ]

Secondary Outcome Measures :
  1. Safety of preoperative regimen [ Time Frame: Treatment to Surgery ]
  2. Determine clinical response rate [ Time Frame: Time of surgery ]
  3. Histopathological axillary nodal status after neoadjuvant therapy [ Time Frame: Time of surgery ]
  4. Correlate baseline and change in tumor and serum genetic, gene expression and proteomic patterns with clinical and pathological response [ Time Frame: Baeline till time of surgery ]
  5. pCR rate at surgery [ Time Frame: Treatment ot Surgery ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Unilateral or bilateral primary carcinoma of the breast,
  • Tumor lesion in the breast with a palpable size of >= 2 cm. The lesion has to be measurable in two-dimensions preferably by sonography. In case of inflammatory disease the extent of inflammation can be used as measurable lesion;
  • Patients should have stages of disease in which adjuvant chemotherapy would be considered.
  • Women of childbearing potential must have a negative serum pregnancy test
  • Negative HER-2/neu status
  • Karnofsky Performance status index >= 80%;
  • Normal cardiac function
  • Laboratory requirements:

Absolute neutrophile count (ANC) >= 2,0 x 109/L and Platelets >= 100 x 109/L and Hemoglobin >= 10 g/dL (>= 6.2 mmol/L) INR ≤ 1.5 ULN and PTT ≤ 1.5 ULN within 14 days prior to enrolment ASAT or ALAT < 2.5 x ULN Alkaline phosphatase ≤ 5 UNL. Patients with ASAT and/or ALAT > 1,5 x UNL associated with alkaline phosphatase > 2,5 x UNL are not eligible for the study Total bilirubin < 1 X UNL Creatinine ≤ 175 µmol/L (2 mg/dl). The calculated creatinine clearance should be ≥ 60 mL/min.

Paraffin tumor tissue block and each one serum and one plasma sample centrally made available

  • Complete staging work-up within 3 months prior to registration.
  • Patients must be available and compliant for treatment and follow-up. Patients registered on this trial must be treated and followed up at the participating or a cooperating center.

Exclusion Criteria:

  • Patients with low or moderate risk, which are only doubtful candidates for adjuvant chemotherapy and do not fulfil the inclusion criteria No. 5.
  • Evidence of distant metastasis;
  • Prior chemotherapy for any malignancy;
  • Prior radiation therapy for breast cancer;
  • Preexisting rhagades at hand and feet and other skin problems (e.g. psoriasis)
  • Pregnant or lactating patients.
  • Pre-existing motor or sensory neuropathy of a severity >= grade 2 by NCI criteria; 7. Concurrent treatment with: Chronic corticosteroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone or equivalent); Sex hormones. Prior treatment must be stopped before study entry; Patients with increased risk of bleeding due to concurrent therapeutic or prophylactic anticoagulative treatment. Low dose of coumarines are permitted.

Other experimental drugs or any other anti-cancer therapy; Drugs recognized as being strong inhibitors or inducers of the isoenzyme CYP3A within the last 5 days or their expected need 8. Other serious illness or medical condition:

  • Previous malignant disease without being disease-free of less than 5 years (except CIS of the Cervix and non-melanomatous skin cancer)
  • Known or suspected congestive heart failure (≥NYHA II) and/or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, un- or poorly controlled arterial hypertension, rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease
  • Thrombotic or embolic events
  • Hemorrhage/bleeding event ≥ Grade 3 within 4 weeks prior study entry
  • Evidence or history of bleeding diathesis or coagulopathy
  • History of significant neurological or psychiatric disorders
  • Patients with seizure disorders requiring medication such as steroids or antiepileptics
  • Currently active infection
  • History of HIV infection or chronic hepatitis B or C
  • Serious non healing wound, ulcer or bone fracture
  • Patients with prior immunosuppressive treatment
  • Severe pulmonary condition/illness
  • Disease significantly affecting gastrointestinal function,
  • Patients with severe liver disease
  • Major surgery, open biopsy or significant traumatic injury within 4 weeks of first dose of study drug
  • Definite contraindications for the use of corticosteroids
  • Inadequate general condition (not fit for anthracycline/taxane-containing chemotherapy)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00548899

St. Gertrauden Krankenhaus
Berlin, Germany, 10713
Klinikum der J. W. Goethe Universität
Frankfurt am Main, Germany, 60590
Hannover, Germany, 30559
Elisabeth Krankenhaus
Kassel, Germany, 34177
Universitätsklinikum Schleswig-Holstein Campus Kiel
Kiel, Germany, 24105
Klinikum der Universität zu Köln
Köln, Germany, 50924
Klinikum Offenbach
Offenbach, Germany, 63069
Klinikum Südstadt
Rostock, Germany, 18059
Dr.-Horst-Schmidt-Kliniken GmbH
Wiesbaden, Germany, 65199
Sponsors and Collaborators
German Breast Group
Study Chair: Sibylle Loibl, MD GBG Forschungs GmbH

Additional Information:
Publications of Results:
Responsible Party: German Breast Group Identifier: NCT00548899     History of Changes
Other Study ID Numbers: GBG 45
2007-000124-41 ( EudraCT Number )
First Posted: October 24, 2007    Key Record Dates
Last Update Posted: March 9, 2015
Last Verified: March 2015

Keywords provided by German Breast Group:
Neoadjuvant chemotherapy
Targeted therapy

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Breast Diseases
Skin Diseases
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vitamin B Complex
Growth Substances
Physiological Effects of Drugs